Pizotifen
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Pizotifen
Pizotifen
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Pizotifen, so there is currently no new predicted indication. The drug’s own recorded uses are listed below; for this drug, none are recorded.
Quick overview
| Item | Content |
|---|---|
| Known uses recorded for this drug | 0 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13866T | Sandomigran 0.5 | Tablet 500 micrograms (as malate) | Valid |
Safety Considerations
- Drug interactions: The interaction query completed, but it returned only a pharmacology target record (the 5-HT1A receptor), not drug-drug interactions.
- Anticholinergic activity: Pizotifen’s weak anticholinergic activity is a theoretical concern in susceptible eyes (for example, narrow-angle glaucoma).
- Weight gain and tolerability: Weight gain is a recognised adverse effect of migraine prophylactic therapy, and a 6-month cohort study (PMID 16362700) included pizotifen. Withdrawals due to side effects were reported in older trials.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications, which were not available in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.